Multiple Myeloma and Osteoporosis: How Bone Damage from Cancer Worsens Fracture Risk
The Dual Bone Threat
Multiple myeloma (MM) and osteoporosis both weaken bone—but through distinct, synergistic mechanisms. MM patients have 2–4× higher fracture risk than age-matched controls, even after adjusting for bone density.
How Myeloma Destroys Bone
- RANKL/OPG dysregulation: Myeloma cells and stromal cells overexpress RANKL, suppress OPG → uncontrolled osteoclast activation → lytic lesions
- Osteoblast suppression: DKK1, sclerostin, IL-3, TNF-α inhibit bone formation → "uncoupled" remodeling (resorption without repair)
- Direct tumor invasion: Marrow replacement, cortical destruction
- Renal impairment: Reduced 1,25-vitamin D synthesis → secondary hyperparathyroidism → bone resorption
- Hypogonadism: Common in men with MM; accelerates bone loss
- Glucocorticoids (dexamethasone): Backbone of MM regimens; direct osteoblast toxicity, reduced calcium absorption, increased excretion
Osteoporosis Compounds the Risk
- Age-related bone loss + MM bone disease = additive fragility
- Vertebral compression fractures (VCFs) cause kyphosis, height loss, chronic pain, respiratory compromise
- Femoral neck fractures → loss of independence, mortality
Bone-Directed Therapy: Standard of Care
| Agent | Dosing | Key Points |
|---|---|---|
| Zoledronic acid (Zometa) | 4 mg IV q4wks (adjust for CrCl); load q3–4mo after 1–2 yrs if stable | Reduces SREs by 30–40%; renal monitoring required; ONJ risk ~1–2% |
| Denosumab (Xgeva) | 120 mg SC q4wks + Ca/Vit D | Non-inferior to zoledronic for SREs; no renal adjustment; ONJ similar; hypocalcemia risk; rebound vertebral fractures on discontinuation → transition to bisphosphonate |
Start at diagnosis for all MM with bone involvement (lytic lesions, osteoporosis, fracture). Continue indefinitely while on active therapy.
Comprehensive Bone Health Strategy
- Baseline: DEXA (spine/hip), lateral spine X-rays (VFA for occult VCFs), Ca, 25-OH-D, PTH, bone turnover markers (CTX, P1NP)
- Calcium: 1200 mg/day total (diet + supplement); citrate preferred if on PPI
- Vitamin D: Target 25-OH-D 40–60 ng/mL (higher than general population)
- Exercise: Weight-bearing + resistance 3×/week; balance training; avoid spinal flexion (VCF risk)
- Fall prevention: Home safety, vision check, medication review, hip protectors if high risk
- Lifestyle: Smoking cessation, alcohol moderation
- Monitoring: DEXA q1–2 yrs; height measurement annually; clinical fracture assessment
Vertebral Fracture Management
- Acute: Analgesia, brief rest, early mobilization, bracing (controversial)
- Kyphoplasty/vertebroplasty: Consider for refractory pain; cement leakage risk in lytic lesions
- Radiation: For painful lytic lesions/plasmacytomas (8 Gy × 1 or 20 Gy/5)
Bone health is not ancillary in myeloma—it's central to survival and quality of life. Integrate bone-directed therapy from day one and maintain vigilance throughout the disease course.
Osteoporosis - Related Articles
- Osteoporosis: A Chronic, Manageable Condition — Not a Terminal Disease
- Pinolenic Acid for Osteoporosis Prevention: A Research Overview
- Understanding Alendronate Sodium (Fosamax) Packaging & Use
- Understanding Osteoporosis: Impact on the Body and Risk Factors
- Osteoporosis Symptoms: Recognizing the Silent Bone Disease
- Osteoporosis Specialists: Which Doctors Diagnose and Treat Bone Loss
- Understanding Osteoporosis: Risks, Symptoms & Prevention
